{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T16:03:52Z","timestamp":1780502632650,"version":"3.54.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,3,21]],"date-time":"2018-03-21T00:00:00Z","timestamp":1521590400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,3,21]],"date-time":"2018-03-21T00:00:00Z","timestamp":1521590400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["U-01 58369"],"award-info":[{"award-number":["U-01 58369"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s10620-018-5023-6","type":"journal-article","created":{"date-parts":[[2018,3,21]],"date-time":"2018-03-21T10:23:14Z","timestamp":1521627794000},"page":"1654-1666","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Acute Liver Failure from Tumor Necrosis Factor-\u03b1 Antagonists: Report of Four Cases and Literature Review"],"prefix":"10.1007","volume":"63","author":[{"name":"for the United States Acute Liver Failure Study Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverley","family":"Kok","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica L. W.","family":"Lester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William M.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. James","family":"Hanje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Todd","family":"Stravitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safwat","family":"Girgis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishali","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua R.","family":"Peck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Esber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine J.","family":"Karvellas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,21]]},"reference":[{"key":"5023_CR1","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/j.1365-2036.2010.04262.x","volume":"31","author":"S Bezabeh","year":"2010","unstructured":"Bezabeh S, Flowers CM, Kortepeter C, Avigan M. Clinically significant liver injury in patients treated with natalizumab. Aliment Pharmacol Ther. 2010;31:1028\u20131035.","journal-title":"Aliment Pharmacol Ther"},{"key":"5023_CR2","unstructured":"FDA. Briefing document: Arthritis Advisory Committee., City. http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/03\/transcripts\/3930T1.htm;2003"},{"key":"5023_CR3","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.cgh.2012.12.025","volume":"11","author":"M Ghabril","year":"2013","unstructured":"Ghabril M, Bonkovsky HL, Kum C, et al. Liver injury from tumor necrosis factor-alpha antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol.. 2013;11:558\u2013564.e553.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"5023_CR4","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.cld.2013.07.001","volume":"17","author":"WM Lee","year":"2013","unstructured":"Lee WM. Drug-induced acute liver failure. Clin Liver Dis. 2013;17:575\u2013586, viii.","journal-title":"Clin Liver Dis"},{"key":"5023_CR5","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1002\/lt.24347","volume":"22","author":"KR Reddy","year":"2015","unstructured":"Reddy KR, Ellerbe C, Schilsky M, et al. Determinants of outcome among patients with acute liver failure listed for liver transplantation in the US. Liver Transpl. 2015;22:505\u2013515.","journal-title":"Liver Transpl"},{"key":"5023_CR6","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/0140-6736(93)91818-7","volume":"342","author":"JG O\u2019Grady","year":"1993","unstructured":"O\u2019Grady JG, Schalm SW, Williams R. Acute liver failure: redefining the syndromes. Lancet (London, England). 1993;342:273\u2013275.","journal-title":"Lancet (London, England)"},{"key":"5023_CR7","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/0895-4356(93)90102-7","volume":"46","author":"C Benichou","year":"1993","unstructured":"Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs\u2013II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol. 1993;46:1331\u20131336.","journal-title":"J Clin Epidemiol"},{"key":"5023_CR8","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/0895-4356(93)90101-6","volume":"46","author":"G Danan","year":"1993","unstructured":"Danan G, Benichou C. Causality assessment of adverse reactions to drugs\u2013I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993;46:1323\u20131330.","journal-title":"J Clin Epidemiol"},{"key":"5023_CR9","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1007\/s10067-005-0169-y","volume":"26","author":"GJ Tobon","year":"2007","unstructured":"Tobon GJ, Canas C, Jaller JJ, Restrepo JC, Anaya JM. Serious liver disease induced by infliximab. Clin Rheumatol. 2007;26:578\u2013581.","journal-title":"Clin Rheumatol"},{"key":"5023_CR10","doi-asserted-by":"publisher","first-page":"38","DOI":"10.5414\/CPP49038","volume":"49","author":"S Hagel","year":"2011","unstructured":"Hagel S, Bruns T, Theis B, Herrmann A, Stallmach A. Subacute liver failure induced by adalimumab. Int J Clin Pharmacol Ther. 2011;49:38\u201340.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"5023_CR11","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.crohns.2012.02.004","volume":"6","author":"U Kinnunen","year":"2012","unstructured":"Kinnunen U, Farkkila M, Makisalo H. A case report: ulcerative colitis, treatment with an antibody against tumor necrosis factor (infliximab), and subsequent liver necrosis. J Crohn\u2019s Colitis. 2012;6:724\u2013727.","journal-title":"J Crohn\u2019s Colitis"},{"key":"5023_CR12","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/s13256-015-0730-5","volume":"9","author":"RS Parra","year":"2015","unstructured":"Parra RS, Feitosa MR, Machado VF, Ramalho LN, da Rocha JJ, Feres O. Infliximab-associated fulminant hepatic failure in ulcerative colitis: a case report. J Med Case Rep. 2015;9:249.","journal-title":"J Med Case Rep"},{"key":"5023_CR13","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s00108-017-0205-4","volume":"58","author":"R Forker","year":"2017","unstructured":"Forker R, Escher M, Stange EF. A 20-year-old woman with ulcerative colitis and acute liver failure. Der Internist. 2017;58:985\u2013989.","journal-title":"Der Internist"},{"key":"5023_CR14","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/0168-8278(90)90124-A","volume":"11","author":"C Benichou","year":"1990","unstructured":"Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol. 1990;11:272\u2013276.","journal-title":"J Hepatol"},{"key":"5023_CR15","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/hep.26709","volume":"59","author":"DE Kleiner","year":"2014","unstructured":"Kleiner DE, Chalasani NP, Lee WM, et al. Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology (Baltimore, MD). 2014;59:661\u2013670.","journal-title":"Hepatology (Baltimore, MD)"},{"key":"5023_CR16","unstructured":"Tumor Necrosis Factor Antagonists. https:\/\/livertox.nlm.nih.gov\/\/TumorNecrosisFactorAntagonists.htm"},{"key":"5023_CR17","doi-asserted-by":"publisher","first-page":"4102","DOI":"10.3748\/wjg.v23.i22.4102","volume":"23","author":"T Koller","year":"2017","unstructured":"Koller T, Galambosova M, Filakovska S, et al. Drug-induced liver injury in inflammatory bowel disease: 1-year prospective observational study. World J Gastroenterol. 2017;23:4102\u20134111.","journal-title":"World J Gastroenterol"},{"key":"5023_CR18","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.cgh.2014.07.062","volume":"13","author":"ES Bjornsson","year":"2015","unstructured":"Bjornsson ES, Gunnarsson BI, Grondal G, et al. Risk of drug-induced liver injury from tumor necrosis factor antagonists. Clin Gastroenterol Hepatol. 2015;13:602\u2013608.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5023_CR19","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1111\/apt.13159","volume":"41","author":"E Shelton","year":"2015","unstructured":"Shelton E, Chaudrey K, Sauk J, et al. New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2015;41:972\u2013979.","journal-title":"Aliment Pharmacol Ther"},{"key":"5023_CR20","doi-asserted-by":"publisher","first-page":"7584","DOI":"10.3748\/wjg.v21.i24.7584","volume":"21","author":"S Rodrigues","year":"2015","unstructured":"Rodrigues S, Lopes S, Magro F, et al. Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy: a single center report of 8 cases. World J Gastroenterol. 2015;21:7584\u20137588.","journal-title":"World J Gastroenterol"},{"key":"5023_CR21","doi-asserted-by":"publisher","first-page":"592","DOI":"10.4254\/wjh.v5.i10.592","volume":"5","author":"E Kim","year":"2013","unstructured":"Kim E, Bressler B, Schaeffer DF, Yoshida EM. Severe cholestasis due to adalimumab in a Crohn\u2019s disease patient. World J Hepatol. 2013;5:592\u2013595.","journal-title":"World J Hepatol"},{"key":"5023_CR22","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm . Accessed February 2018"},{"key":"5023_CR23","doi-asserted-by":"publisher","first-page":"705","DOI":"10.2340\/00015555-2644","volume":"97","author":"JH Hoffmann","year":"2017","unstructured":"Hoffmann JH, Knoop C, Enk AH, Hadaschik EN. Routine laboratory parameter dynamics and laboratory adverse events in psoriasis patients on long-term treatment with adalimumab, etanercept, and ustekinumab. Acta Derm Venereol. 2017;97:705\u2013710.","journal-title":"Acta Derm Venereol"},{"key":"5023_CR24","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1080\/03009742.2016.1202318","volume":"46","author":"YM Chiu","year":"2017","unstructured":"Chiu YM, Tang CH, Hung ST, Yang YW, Fang CH, Lin HY. A real-world risk analysis of biological treatment (adalimumab and etanercept) in a country with a high prevalence of tuberculosis and chronic liver disease: a nationwide population-based study. Scand J Rheumatol. 2017;46:236\u2013240.","journal-title":"Scand J Rheumatol"},{"key":"5023_CR25","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40264-015-0366-9","volume":"39","author":"JB French","year":"2016","unstructured":"French JB, Bonacini M, Ghabril M, Foureau D, Bonkovsky HL. Hepatotoxicity associated with the use of anti-TNF-alpha agents. Drug Saf. 2016;39:199\u2013208.","journal-title":"Drug Saf"},{"key":"5023_CR26","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1136\/ard.2009.112136","volume":"69","author":"J Sokolove","year":"2010","unstructured":"Sokolove J, Strand V, Greenberg JD, et al. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis. 2010;69:1612\u20131617.","journal-title":"Ann Rheum Dis"},{"key":"5023_CR27","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1097\/MIB.0000000000000061","volume":"20","author":"KT Park","year":"2014","unstructured":"Park KT, Sin A, Wu M, Bass D, Bhattacharya J. Utilization trends of anti-TNF agents and health outcomes in adults and children with inflammatory bowel diseases: a single-center experience. Inflamm Bowel Dis. 2014;20:1242\u20131249.","journal-title":"Inflamm Bowel Dis"},{"key":"5023_CR28","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1097\/MEG.0000000000000624","volume":"28","author":"I Parisi","year":"2016","unstructured":"Parisi I, O\u2019Beirne J, Rossi RE, et al. Elevated liver enzymes in inflammatory bowel disease: the role and safety of infliximab. Eur J Gastroenterol Hepatol. 2016;28:786\u2013791.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"5023_CR29","first-page":"956463","volume":"2014","author":"R Parekh","year":"2014","unstructured":"Parekh R, Kaur N. Liver injury secondary to anti-TNF-alpha therapy in inflammatory bowel disease: a case series and review of the literature. Case Rep Gastrointest Med. 2014;2014:956463.","journal-title":"Case Rep Gastrointest Med"},{"key":"5023_CR30","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1053\/j.gastro.2009.06.006","volume":"137","author":"WM Lee","year":"2009","unstructured":"Lee WM, Hynan LS, Rossaro L, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology.. 2009;137:856\u2013864, 864.e851.","journal-title":"Gastroenterology."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-018-5023-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-5023-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-5023-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T05:27:56Z","timestamp":1719898076000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-018-5023-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,21]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["5023"],"URL":"https:\/\/doi.org\/10.1007\/s10620-018-5023-6","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,21]]},"assertion":[{"value":"5 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}